Radiopharm Theranostics Limited (RAD.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.004 (+0.00%) as of
Key statistics
- Market cap
- 17.51M
- Forward P/E
- -0.27
- EPS (TTM)
- -0.0100
- Dividend yield
- 0.00%
- 52-week range
- 0.0035 – 0.0370
- Beta
- 0.86
- Revenue (TTM)
- 12.87M
- Profit margin
- 0.00%
- Analyst target
- A$0.146373
- Volume
- 121.31k
About Radiopharm Theranostics Limited
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Carlton, VIC, Australia
- Employees
- 14
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.